HEADER PROTEIN BINDING 09-APR-17 5VFW TITLE AN ENGINEERED CYCLIC PEPTIDE ALLEVIATES SYMPTOMS OF INFLAMMATION IN A TITLE 2 MURINE MODEL OF INFLAMMATORY BOWEL DISEASE COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANNEXIN A1; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N TERMINAL ANNEXIN I (2-26); COMPND 5 SYNONYM: ANNEXIN I,ANNEXIN-1,CALPACTIN II,CALPACTIN-2,CHROMOBINDIN-9, COMPND 6 LIPOCORTIN I,PHOSPHOLIPASE A2 INHIBITORY PROTEIN,P35; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 SYNTHETIC: YES; SOURCE 3 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 4 ORGANISM_COMMON: HUMAN; SOURCE 5 ORGANISM_TAXID: 9606 KEYWDS STRUCTURE FROM CYANA 3.97, PROTEIN BINDING EXPDTA SOLUTION NMR NUMMDL 20 AUTHOR N.L.DALY,C.COBOS CACERES REVDAT 4 14-JUN-23 5VFW 1 REMARK REVDAT 3 28-JUN-17 5VFW 1 JRNL REVDAT 2 24-MAY-17 5VFW 1 JRNL REVDAT 1 10-MAY-17 5VFW 0 JRNL AUTH C.COBOS CACERES,P.S.BANSAL,S.NAVARRO,D.WILSON,L.DON, JRNL AUTH 2 P.GIACOMIN,A.LOUKAS,N.L.DALY JRNL TITL AN ENGINEERED CYCLIC PEPTIDE ALLEVIATES SYMPTOMS OF JRNL TITL 2 INFLAMMATION IN A MURINE MODEL OF INFLAMMATORY BOWEL JRNL TITL 3 DISEASE. JRNL REF J. BIOL. CHEM. V. 292 10288 2017 JRNL REFN ESSN 1083-351X JRNL PMID 28473469 JRNL DOI 10.1074/JBC.M117.779215 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CYANA REMARK 3 AUTHORS : GUNTERT, MUMENTHALER AND WUTHRICH REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 5VFW COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 10-APR-17. REMARK 100 THE DEPOSITION ID IS D_1000227124. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 290 REMARK 210 PH : 5 REMARK 210 IONIC STRENGTH : 1 REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : 0.2 MM AC 2-26, 90% H2O/10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 2D 1H-1H TOCSY; 2D 1H-1H COSY; REMARK 210 2D 1H-1H NOESY; 2D 1H-13C HSQC; REMARK 210 2D 1H-15N HSQC REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ REMARK 210 SPECTROMETER MODEL : AVANCE III REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : CCPNMR, TOPSPIN, TALOS, CYANA REMARK 210 METHOD USED : TORSION ANGLE DYNAMICS REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : 100 REMARK 210 CONFORMERS, NUMBER SUBMITTED : 20 REMARK 210 CONFORMERS, SELECTION CRITERIA : TARGET FUNCTION REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 1 GLN A 9 -31.83 -134.15 REMARK 500 2 GLN A 9 -31.77 -134.19 REMARK 500 3 GLN A 9 -31.81 -134.20 REMARK 500 4 SER A 4 52.35 -116.02 REMARK 500 4 GLN A 9 -31.83 -134.16 REMARK 500 4 THR A 23 98.42 -66.65 REMARK 500 5 SER A 4 52.37 -117.11 REMARK 500 5 GLN A 9 -31.82 -134.14 REMARK 500 6 GLN A 9 -31.73 -134.21 REMARK 500 7 SER A 4 52.34 -119.69 REMARK 500 7 GLN A 9 -31.83 -134.22 REMARK 500 8 GLN A 9 -31.80 -134.19 REMARK 500 9 GLN A 9 -31.73 -133.98 REMARK 500 9 ASN A 15 40.15 -102.41 REMARK 500 9 GLU A 17 35.38 -99.70 REMARK 500 10 GLN A 9 -31.81 -133.90 REMARK 500 10 ASN A 15 41.24 -108.34 REMARK 500 11 GLN A 9 -31.81 -133.97 REMARK 500 11 GLU A 17 35.42 -97.71 REMARK 500 12 GLN A 9 -31.76 -133.97 REMARK 500 13 GLN A 9 -31.83 -133.79 REMARK 500 14 SER A 4 49.23 -109.09 REMARK 500 14 GLN A 9 -31.78 -133.90 REMARK 500 14 ASN A 15 97.86 -60.85 REMARK 500 15 GLN A 9 -31.85 -133.78 REMARK 500 15 ASN A 15 36.77 -96.57 REMARK 500 16 SER A 4 49.36 -107.00 REMARK 500 16 GLN A 9 -31.79 -133.77 REMARK 500 16 GLU A 17 35.40 -97.12 REMARK 500 17 GLN A 9 -31.76 -134.02 REMARK 500 18 GLN A 9 -31.56 -133.73 REMARK 500 18 GLU A 17 35.45 -97.28 REMARK 500 19 SER A 4 52.46 -110.25 REMARK 500 19 GLN A 9 -31.70 -134.25 REMARK 500 19 GLU A 17 35.40 -95.67 REMARK 500 19 TYR A 20 -178.64 -172.74 REMARK 500 20 GLN A 9 -31.57 -134.22 REMARK 500 20 ASN A 15 43.27 -97.39 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 30281 RELATED DB: BMRB REMARK 900 AN ENGINEERED CYCLIC PEPTIDE ALLEVIATES SYMPTOMS OF INFLAMMATION IN REMARK 900 A MURINE MODEL OF INFLAMMATORY BOWEL DISEASE REMARK 900 RELATED ID: 5VAV RELATED DB: PDB DBREF 5VFW A 1 25 UNP P04083 ANXA1_HUMAN 2 26 SEQRES 1 A 25 ALA MET VAL SER GLU PHE LEU LYS GLN ALA TRP PHE ILE SEQRES 2 A 25 GLU ASN GLU GLU GLN GLU TYR VAL GLN THR VAL LYS HELIX 1 AA1 PHE A 6 TRP A 11 1 6 HELIX 2 AA2 GLU A 14 GLN A 18 5 5 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MODEL 1